Discover 1,621 paid clinical trials in Durham, North Carolina. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,621
Improving Outcomes in Early Menopause After Cancer
for
Early Menopause, Cancer, Premature Menopause,
Location: Durham NC
Sponsor: Duke University
Sex: Female
Age: 18 - 44
Code: NCT06982677
Recruiting
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
for
KRAS Altered Advanced or Metastatic Solid Tumors
Location: Durham NC, Fairfax VA, Philadelphia PA, Atlanta GA,
Sponsor: Amgen
Sex: All
Age: 18+
Code: NCT07094113
Phase1, Recruiting
Pilot Study of Mindset Moments Among Adolescent and Young Adult Cancer Survivors
for
Cancer, Youth Cancer, Young Adult Cancer,
Location: Durham NC
Sponsor: Duke University
Sex: All
Age: 19 - 25
Code: NCT06732375
Recruiting
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
for
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma,
Location: Durham NC, Fairfax VA, Atlanta GA, Hackensack NJ,
Sponsor: Astellas Pharma Global Development, Inc.
Sex: All
Age: 18+
Code: NCT07488676
Phase1, Phase2, Recruiting
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
for
Carcinoma, Hepatocellular, Hepatocellular Cancer,
Location: Durham NC, Cary NC, Raleigh NC, Land O' Lakes FL,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT07227012
Phase1, Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
for
Breast Neoplasms
Location: Durham NC, Midlothian VA, Greenville SC, Winchester VA,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT06926868
Phase2, Phase3, Recruiting
Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
for
Cancer, Breast Cancer, Colorectal Cancer, Sarcoma, Lymphoma,
Location: Durham NC
Sponsor: Duke University
Sex: All
Age: 18 - 39
Code: NCT06371768
Recruiting
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
for
Renal Cell Carcinoma
Location: Durham NC, Pittsburgh PA, New York NY, Mineola NY,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18 - 70+
Code: NCT07049926
Phase1, Phase2, Recruiting
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
for
Gastric or Gastroesophageal Junction Adenocarcinoma,
Location: Durham NC, Fairfax VA, Pittsburgh PA, Louisville KY,
Sponsor: Phanes Therapeutics
Sex: All
Age: 18+
Code: NCT05482893
Phase1, Phase2, Recruiting
Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma
Location: Durham NC, Chapel Hill NC, Santa Monica CA
Sponsor: NanoCarrier Co., Ltd.
Sex: All
Age: 18 - 70+
Code: NCT03168061
Phase1, Phase2, Recruiting
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
for
Colorectal Neoplasms
Location: Durham NC, Pinehurst NC, Roanoke VA, Salem VA,
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Sex: All
Age: 18+
Code: NCT05253651
Phase3, Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
for
Triple Negative Breast Cancer
Location: Durham NC, Chapel Hill NC, Greensboro NC,
Sponsor: Gilead Sciences
Sex: All
Age: 18+
Code: NCT05633654
Phase3, Recruiting
Engage Psychosocial Intervention for Cancer Symptoms
for
Advanced Breast Cancer, Advanced Prostate Cancer,
Location: Durham NC
Sponsor: Duke University
Sex: All
Age: 18+
Code: NCT06555588
Recruiting
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)